Marksans Pharma Ltd Share Price Today - Marksans Pharma Ltd Stock Price Live NSE/BSE

Marksans Pharma Ltd

NSE: MARKSANS BSE: 524404

₹203.28

(2.79%)

Tue, 19 May 2026, 03:51 am

MTF 5xInvest in Marksans Pharma Ltd with 5x Leverage Buy with MTF

Market Cap89.68B

PE Ratio25.57

Dividend0.40

Health Technology

Pharmaceuticals: Major

24.5K

Marksans Pharma Share Price Live Chart

1 Day

(2.79%)

No Result Found

Summary

Market Cap
9863.11
Net Profit
382.62
P/B
4.08
Sector P/E
35.36
P/E
26.47
EV/EBITDA
16.18
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.95
ROCE (Industry)
16.47
RONW (Industry)
14.44
ROE
16.89
ROCE
20.19
Debt/Equity
0.12
EPS (TTM)
7.95
Dividend Yield
0.37
Book Value
59.32
Interest Cover
44.22

Analysis

all

Pros

Marksans Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Marksans Pharma is profitable, therefore cash runway is not a concern.
Marksans Pharma is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (880.5%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 24.8x debt.

Cons

Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of Marksans Pharma's dividends as it is not paying a notable one for India.
Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are stable.
Marksans Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Marksans Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	43.87	43.87	43.87	43.87	43.87
FII	16.76	8.12	16.92	19.88	22.20
DII	6.57	5.91	5.28	5.50	4.56
Public	32.79	42.09	33.93	30.75	29.37
Government	0	0	0	0	0

Technical Analysis

RSI

72.84

MACD

9.41

50 DMA

180.25

200 DMA

181.95

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	250.46	215.38	200.01	180.30	164.93	145.22	110.14
Fibonacci	215.38	201.98	193.70	180.30	166.90	158.62	145.22
Camarilla	194.28	191.06	187.85	180.30	181.41	178.20	174.98

Pivots Level: Classic

+70.16

250.46

+35.08

215.38

+19.70

200.01

180.30

Pivot Point

LTP: 220.30

-15.38

164.93

-35.08

145.22

-70.16

110.14

Moving Average

SMAEMA

Period

Value

10-EMA
205.45
20-EMA
197.45
30-EMA
192.31
50-EMA
186.73
100-EMA
183.58
200-EMA
189.44

Announcement Date	Purpose	Action	Ex Date
05 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results, Nine Months Results
11 Jul 2025	agm
01 Jul 2025	dividend	Final Dividend - Rs. - 0.8	01 Aug 2025
19 May 2025	dividend	₹0.80 Dividend /Share	01 Aug 2025
19 Aug 2024	agm
17 Aug 2024	dividend	Final Dividend - Rs. - 0.6	17 Sept 2024
30 May 2024	dividend	₹0.60 Dividend /Share	17 Sept 2024
02 Aug 2023	agm
30 May 2023	dividend	₹0.50 Dividend /Share	07 Jun 2023

Marksans Pharma Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Cipla Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Marksans Pharma Ltd About

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers, one located in Goa and the other in Navi Mumbai.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1992

Headquarters

CEO

Mark Saldanha

Employees

Contact

Website

http://www.marksanspharma.com

companysecretary@marksanspharma.com ; info@marksan

Phone

91-22-40012000

Location

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Year	History
2017	Marksans Pharma Goa plant received UK MHRA approval. Marksans Pharma received certificate of GMP Compliance of a Manufacturer from Australian government, Department of Health, Therapeutic Goods Administration.
2021	Marksans Pharma received USFDA approval for Acetaminophen ER Tablets.
2022	The company completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE. Marksans Pharma received USFDA approval for Cetirizine Hydrochloride Tablets. Marksans Pharma received UK MHRA approval for Bells Healthcare All in One Oral Solution.
2023	Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited received Marketing Authorisation for Cyanocobalamin 50mg film coated tablets. Marksans Pharma completed the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India. Marksans Pharma received UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.
2024	Marksans Pharma Limited receives USFDA approval for Loratadine Tablets USP 10mg. US FDA Inspection at Marksans Pharma's manufacturing facility located at Verna, Goa was successfully closed.

Client Name	Deal Type	Order Side	QTY	Avg Price	Date
UNIFI CAPITAL PRIVATE LIMITED	bulk	Buy	7241309	231.5	28 Jul 2025
UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI	block	Buy	3247600	249.95	11 Jun 2025
SOCIETE GENERALE	block	Buy	920184	249.95	11 Jun 2025
UNIFI CAPITAL PRIVATE LIMITED	block	Buy	594000	249.95	11 Jun 2025
UNIFI BLEND FUND 2	block	Buy	3000000	249.95	11 Jun 2025
UNIFI BCAD FUND	block	Buy	560000	249.95	11 Jun 2025
UTI MUTUAL FUND	block	Buy	414093	249.95	11 Jun 2025
CITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITED	block	Buy	400081	249.95	11 Jun 2025
BANDHAN MUTUAL FUND	block	Buy	600000	249.95	11 Jun 2025
SUBHKAM VENTURES I PRIVATE LIMITED	block	Buy	537485	249.95	11 Jun 2025

Marksans Pharma Ltd News

Marksans Pharma Board Meet on May 26 for Q4FY26 Results

Marksans Pharma schedules board meeting on May 26, 2026, to approve Q4FY26 audited financial results and consider dividend recommendation for FY2025-26.

12 May 2026

companies

Marksans Pharma Files SEBI Compliance Certificate

Marksans Pharma Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4 FY26, confirming proper handling of dematerialized securities through its registrar Bigshare Services.

09 Apr 2026

companies

Marksans Pharma Gets USFDA Nod for Benzonatate Capsules

Marksans Pharma receives USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg strengths, expanding its US pharmaceutical portfolio with this cough suppressant medication.

01 Apr 2026

companies

Marksans Pharma Gets USFDA Nod for Benzonatate Capsules

Marksans Pharma receives USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg strengths, expanding its US pharmaceutical portfolio with this cough suppressant medication.

01 Apr 2026

companies

Marksans Pharma Opens Special Window for Share Transfer

Marksans Pharma announces SEBI-mandated special window for re-lodgment of physical share transfer requests from pre-April 2019 transactions, valid from February 5, 2026 to February 4, 2027.

11 Mar 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800